No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Hong Kong's Department of Health: To develop Hong Kong into a gateway for the internationalization of traditional Chinese medicine and Chinese herbal medicine.
Secretary for Food and Health of the Hong Kong Special Administrative Region, Dr. Constance Chan, stated that in order to promote the standardization and internationalization of traditional chinese medicine, Hong Kong aims to become a gateway for the internationalization of traditional chinese medicine.
China Shineway Pharmaceutical Group Limited (HKG:2877) Top Key Executive Zhenjiang Li's Holdings Dropped 8.0% in Value as a Result of the Recent Pullback
shineway pharm (02877) had a turnover of 2.887 billion yuan in the first three quarters, a year-on-year decrease of 16.9%.
Shineway Pharm (02877) announced that as of September 30, 2024, the nine months ended have not been reviewed by auditors...
China Shineway Pharmaceutical Group Limited's (HKG:2877) 30% Share Price Surge Not Quite Adding Up
